Libo Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	337.66	275.42	75.26
Cash & Short-Term Investments	337.66	275.42	75.26
Cash Growth	-	265.95%	-
Other Receivables	0.33	0.54	0.56
Receivables	0.33	0.54	0.56
Inventory	1.74	1.74	2.02
Prepaid Expenses	26.32	12.74	0.47
Total Current Assets	366.04	290.44	78.32
Property, Plant & Equipment	3.79	3.71	3.4
Other Intangible Assets	159.21	168.78	13.54
Other Long-Term Assets	3.81	4.93	4.42
Total Assets	532.85	467.87	99.67
Accrued Expenses	20.73	6.19	7.17
Current Portion of Leases	1.58	1.56	1.07
Other Current Liabilities	35.08	0.45	0.35
Total Current Liabilities	57.38	8.21	8.59
Long-Term Leases	0.63	1.42	2.11
Total Liabilities	58.01	9.62	10.7
Common Stock	431.88	409.23	265.03
Additional Paid-In Capital	72.67	377.63	4.28
Retained Earnings	-116.96	-318.61	-171.33
Comprehensive Income & Other	87.26	-10.01	-9.01
Shareholders' Equity	474.85	458.24	88.98
Total Liabilities & Equity	532.85	467.87	99.67
Total Debt	2.2	2.98	3.19
Net Cash (Debt)	335.45	272.45	72.08
Net Cash Growth	-	277.99%	-
Net Cash Per Share	8.21	7.27	2.72
Filing Date Shares Outstanding	43.19	40.92	26.5
Total Common Shares Outstanding	43.19	40.92	26.5
Working Capital	308.66	282.24	69.73
Book Value Per Share	10.99	11.20	3.36
Tangible Book Value	315.63	289.47	75.44
Tangible Book Value Per Share	7.31	7.07	2.85
Machinery	3.68	2.82	9.33
Leasehold Improvements	0.48	0.48	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.